Hints and tips:
Related Special Reports
...The Development Bank of Japan is investing in 4Bio, which funds companies in the UK and Europe, alongside the Japanese pharma group Kyowa Kirin, and US healthcare provider, Children’s Minnesota. 4Bio aims...
...Under such “risk-based contracts”, healthcare providers could spread the cost over a longer period during which they could see savings, for example, from not having to treat as many expensive heart attacks...
...pushing into the US healthcare industry by launching online services such as video calls with doctors, and earlier this year closing a $3.9bn deal to acquire One Medical, a subscription-based healthcare provider...
...But the truth is, there is a difference in how men and women are supported by healthcare systems and providers....
...Data provider Pharmcube reported that investment on new drug discovery in China fell by 32 per cent in 2023 to $4.8bn....
...However lawyers and executives warn that the change may inadvertently compel companies to switch to Russian providers, or instead provide these services from offices outside the EU....
...Biosimilars shot up from a 2 per cent share of all Humira prescriptions at the end of March to 19 per cent by mid-April, according to data provider IQVIA....
...UK companies reporting full-year results include real estate agent Foxtons, bakery chain Greggs, insurer Hiscox, office space provider IWG and news publisher Reach....
...Over 6 per cent of prescription sales will lose patent protection in 2028, the highest level since 2015, according to data provider Evaluate....
...Venture capital investment in gene editing dropped last year along with other biotech investments, falling from $2.45bn in 2022 to $1.06bn in 2023, according to data provider PitchBook....
...But healthcare providers must also decide whether weight-loss drugs represent value for money....
...The number of positions offered grew by 43 per cent annually across the top 10 pharmaceutical companies alone since 2018....
...Although the 21.1 per cent uptake of the GSK and Pfizer jabs is comfortably ahead of the 18 per cent forecast by health data provider Airfinity, GSK’s Arexvy jab has accounted for more than two-thirds of...
...The warning came as the Department of Health and Social Care this week told healthcare providers not to prescribe diabetes medication for non-licensed purposes such as weight loss, and for existing stock...
...Many biotechs hoping to enter the market will aim for partnerships with larger groups, a well-trodden path in the pharmaceutical industry....
...Frankfurt has only had two this year: German green hydrogen producer Nucera and web hosting services provider Ionos....
...Last year KKR-backed cancer treatment provider GenesisCare was unable to borrow the money it needed from existing lenders, chief executive David Young told a US court, in part because of a restrictive whitelist...
...Walgreens acquired urgent-care provider Summit Health-City MD and post-acute home-care provider CareCentrix. But the transition has been slow....
...Last month, Swiss pharmaceutical company Roche agreed an up to $3.1bn takeover of obesity drug developer Carmot Therapeutics....
...In early October, when Novo Nordisk announced that Ozempic was so effective against kidney disease that it was stopping a trial early, shares in some dialysis providers tanked....
...“Flu and Covid-19 represent a significant seasonal burden for individuals, providers, healthcare systems and economies,” he said....
...Everything from manufacturing machinery to pharmaceutical recipes or software could be collateralised efficiently, and without the costs of escrow or other security guarantees....
...Data provider Startup Heatmap Europe ranks it third, behind London and Berlin, while online publication EU-Startups.com ranks it sixth....
...Shanghai’s stock exchange, which jointly owns the China Securities Index Company together with its counterpart in Shenzhen, told state media this week that it would ensure the index provider “enriches the...
...Healthcare providers in the US wrote more than 9mn prescriptions for Ozempic and similar weight loss and diabetes drugs in the final quarter of 2022, as demand soars for the blockbuster treatments....
International Edition